Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints
(RTTNews) - Celldex Therapeutics, Inc. (CLDX) on Thursday stated it is discontinuing development of barzolvolimab in atopic dermatitis (AD) after the Phase 2 trial missed its primary and secondary endpoints.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.